A Leader in the Biosciences

The Scripps Research Institute (TSRI) is an international leader in the application of biomedical research to develop life-saving drug and other therapies. It is one of the world's largest independent nonprofit biomedical research organizations, growing out of the Scripps Metabolic Clinic founded in California in 1924. In 2004, the institute expanded into Florida.

The mission of The Scripps Research Institute is to serve humanity by

  • Creating basic knowledge in the biosciences
  • Applying breakthroughs in research to the advancement of medicine
  • Educating and training young scientists for biomedical research and its application

Over the last decades, TSRI has become internationally recognized for research in autoimmune diseases, cancer, cardiovascular disorders, cell biology, chemistry, immunology, molecular biology, neuropharmacology and neurosciences. The Florida campus also provides advanced robotics and chemical screening to provide faster commercialization of scientific discoveries, speeding benefits to patients.

This research continues to benefit the clinical prevention, diagnosis, and treatment of diseases including stroke and heart disease, cancer, neurodegenerative diseases of aging, infectious diseases, alcoholism and chemical dependency, diabetes and other metabolic disorders, autoimmune diseases, kidney dysfunction, and neurological and psychiatric disorders, including autism and schizophrenia.

TSRI in California has 1 million square feet of laboratory space and operates in 15 buildings on Torrey Pines Mesa, in the heart of one of the country's leading biotechnology centers, in La Jolla, a part of the City of San Diego.

TSRI in Florida is located on 350,000 square feet in three buildings on 30 acres adjacent to the Florida Atlantic University campus.

Major Scientific Achievements

Scientists at TSRI are responsible for seminal studies into the basic biology of molecules and cells that are at the root of all life. During the past two decades, scientists at the Institute have...read more

Faculty and Staff

Under the leadership of its CEO and Vice  Chair, Peter G. Schultz, Ph.D., and President, Steve A. Kay, Ph.D., D.Sc., TSRI’s personnel of 2,900 includes:

  • 2 Nobel Laureates
  • 17 members of the National Academy of Sciences
  • 16 members of the American Academy of Arts and Sciences
  • 32 Fellows of the American Association for the Advancement of Science
  • 9 members of the National Academy of Medicine

Graduate Education and Postdoctoral Training

Currently, TSRI employs more than 700 postdoctoral fellows and enrolls more than 200 doctoral students in the TSRI graduate program, ranked #2 in biochemistry, #7 overall in chemistry, and #9 overall in biological sciences by U.S. News and World Report. Selected students participate in an historic joint Ph.D.-D.Phil. degree program with Oxford University, the first such collaboration in Oxford's 800-year history.


TSRI is governed by a Board of Trustees comprised of business and philanthropic leaders from throughout the United States. Its advisory Board of Scientific Governors is an international Who's-Who of biomedical research and includes 3 Nobel Laureates.


The Institute's $310 million operating budget includes federal funding, financial incentives from the State of Florida, licensing fees and investment income, grants from health-related research and support organizations, and gifts from private foundations, corporations, and individuals.

Public Programs

The Institute provides year-round lectures and symposia by TSRI faculty and other scientists, annual science fairs and ongoing outreach programs for public and private schools, and summer science internships for high school students and teachers in California and Florida.

Accountability and Transparency

TSRI has been consistently recognized as a coveted four-star charity by Charity Navigator, America’s premier independent charity evaluator, for its exceptional financial health, accountability, and transparency.

donate now

join us

Research at TSRI develops life-saving therapies like Surfaxin®, which helps premature infants breathe. (Play video.)